SCHEMBL3843211

SCHEMBL3843211

O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 20/20 1.00
▸ DPP8 Q6V1X1 9/20 1.00
▸ DPP7 Q9UHL4 9/20 1.00
▸ KCNH2 Q12809 1/20 0.81
▸ FAP Q12884 1/20 0.71
▸ DPP9 Q86TI2 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3842509 0.98 DPP4 (1.00) DPP4DPP8DPP7KCNH2FAP
SCHEMBL3842850 0.90 DPP4 (1.00) DPP4DPP8DPP7KCNH2FAP
SCHEMBL3842848 0.90 DPP4 (1.00) DPP4DPP8DPP7KCNH2FAP
SCHEMBL3843529 0.90 DPP4 (1.00) DPP4DPP8DPP7KCNH2FAP
SCHEMBL3840953 0.87 DPP4 (1.00) DPP4DPP8DPP7KCNH2FAP
SCHEMBL3848283 0.86 DPP4 (1.00) DPP4DPP8DPP7KCNH2FAP
Hydrochloric Acid SCHEMBL3841149 0.85 DPP4 (0.98) DPP4DPP8DPP7KCNH2FAP
SCHEMBL3840882 0.85 DPP4 (1.00) DPP4DPP8DPP7KCNH2FAP
SCHEMBL3842844 0.85 DPP4 (1.00) DPP4DPP8DPP7KCNH2FAP
Hydrochloric Acid SCHEMBL3841151 0.85 DPP4 (0.98) DPP4DPP8DPP7KCNH2FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240115577-A1 SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES THE SCRIPPS RESEARCH INSTITUTE 2024-04-11 — — US disclosed
EP-2116541-B1 Proline derivatives and their use as dipeptidyl peptidase IV inhibitors PFIZER PROD INC (US) 2015-02-25 — — EP disclosed
EP-2116541-A1 Proline derivatives and their use as dipeptidyl peptidase IV inhibitors Pfizer Products Incorporated (US) 2009-11-11 — — EP disclosed
EP-1753748-B1 PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS PFIZER PROD INC (US) 2009-07-29 — — EP disclosed
US-7465732-B2 (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives PFIZER INC (US) 2008-12-16 — — US disclosed
US-7291618-B2 Therapeutic compounds PFIZER INC (US) 2007-11-06 — — US disclosed
US-20070161664-A1 THERAPEUTIC COMPOUNDS PFIZER INC 2007-07-12 — — US disclosed
US-20070099897-A1 Therapeutic compounds PFIZER INC 2007-05-03 — — US disclosed
EP-1753748-A1 PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS Pfizer Products Inc. (US) 2007-02-21 — — EP disclosed
US-20060079498-A1 Therapeutic compounds PFIZER INC 2006-04-13 — — US disclosed
WO-2005116014-A1 PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS PFIZER PRODUCTS INC. (US) 2005-12-08 — — WO disclosed
US-20050256310-A1 Therapeutic compounds PFIZER INC 2005-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256310-A1 Therapeutic compounds REN, SLC5A1, SLC5A2 DPP4 26/4885DPP8 413/4885DPP7 274/4885
US-20070099897-A1 Therapeutic compounds SLC5A2, SLC5A1, REN DPP4 31/4885DPP8 404/4885DPP7 114/4885
US-20070161664-A1 THERAPEUTIC COMPOUNDS SLC5A2, SLC5A1, REN DPP4 31/4885DPP8 404/4885DPP7 114/4885
US-20060079498-A1 Therapeutic compounds SLC5A2, SLC5A1, REN DPP4 31/4885DPP8 404/4885DPP7 114/4885
US-20240115577-A1 SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES DPP4, DPP7, ING2 DPP4 1/4885DPP8 8/4885DPP7 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback